Percentage increase/(decrease) over previous corresponding period
Revenue from ordinary activities
2,116,242
89
Profit/(loss) from ordinary activities after tax attributable to members
(4,002,331)
(25)
Net profit/(loss) for the period attributable to members
(4,002,331)
(25)
Dividends
Amount per security
Franked amount per security
Final dividend
Nil
Nil
Interim dividend
Nil
Nil
Record date for determining entitlements to dividend
Not applicable
Brief explanation of any of the figures reported above necessary to enable the figures to be understood
The increase in revenue is increased R&D tax incentive received due to increased investment in R&D in 2015. Market development activity peaked in calendar 2015 and has reduced in 2016 calendar year.
Income
Statement Refer to Attachment A These accounts are in the process of being audited.
Balance Sheet Refer to Attachment A These accounts are in the process of being audited.
Statement of Changes in Equity
Cash Flow Statement
Refer to Attachment A These accounts are in the process of being audited.
Refer to Attachment A These accounts are in the process of being audited.
Dividends
Date dividend is payable
Not applicable
Record date to determine entitlement to the dividend
Not applicable
Amount per security
Not applicable
Total dividend
Not applicable
Amount per security of foreign sourced dividend or distribution
Not applicable
Details of any dividend reinvestment plans in operation
Not applicable
The last date for receipt of an election notice for participation in any dividend reinvestment plans
Not applicable
Statement of retained earnings
Consolidated Entity
2016
2015
Balance at the beginning of the year
(92,268,467)
(86,952,863)
Net profit attributable to members of the parent entity
(4,0002.331)
(5,316,604)
Transfer from option reserve
Balance at end of the year
(96,270,798)
(92,268,467)
Net tangible assets per security
Current period
Previous corresponding period
Net tangible asset backing per ordinary security
0.05 cents
0.05 cents
Details of entities over which control has been gained or lost during the period
Not applicable
Details of associated and joint venture entities
Name of associate or joint venture entity
% Securities held
PeriCoach Pty Ltd
100
Analytica Limited published this content on 31 August 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 31 August 2016 04:08:07 UTC.
Original documenthttp://www.analyticamedical.com/downloads/2016/20160831-ASX-ALT-Appendix4E.pdf
Public permalinkhttp://www.publicnow.com/view/A9A7F0AE7816B8A126D742BED0C83692A8AF99A4
Analytica Limited is an Australia-based product development and commercialization company that is focused on Class I and II medical device products. Its lead product is the PeriCoach System- an e-health treatment system for women who suffer stress urinary incontinence. PeriCoach includes a device, Web portal and smartphone app and the device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via Web portal. The Company is also the developer of the Enhanced Infusion System (EIS), a combination of technologies developed under the project names AutoStart and AutoFlush. It is also commercializing the AutoStart Burette infusion system. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control and automatically restart flow after medication delivery during intravenous fluid infusion.